<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228591</url>
  </required_header>
  <id_info>
    <org_study_id>CR-1636BB</org_study_id>
    <nct_id>NCT01228591</nct_id>
  </id_info>
  <brief_title>Pilot Dispensing Evaluation of a Plus Power Lens</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the performance of the ACUVUE® ADVANCE® Plus lenses
      against ACUVUE® ADVANCE® lenses in the plus power parameters.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity One Week After Lens Wear</measure>
    <time_frame>1 week</time_frame>
    <description>Visual acuity was measured using ETDRS visual acuity test. ETDRS stands for Early Treatment Diabetic Retinopathy Study. Binocular and monocular measurements were collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Acuity at Time of Initial Fit</measure>
    <time_frame>After 10-15 minutes of lens wear</time_frame>
    <description>Visual acuity will be measured using ETDRS visual acuity test. ETDRS stands for Early Treatment Diabetic Retinopathy Study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Contact Lens Comfort Using Contact Lens User Experience (CLUE)</measure>
    <time_frame>1 week</time_frame>
    <description>The subjective comfort questionnaire CLUE, assesses the overall lens comfort. The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0 to 120.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Reported Vision Using Contact Lens User Experience (CLUE).</measure>
    <time_frame>1 week</time_frame>
    <description>Overall vision was assessed by a subjective vision questionnaire. The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0 to 120.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contact Lens Comfort at Initial Fit Using Contact Lens User Experience (CLUE)</measure>
    <time_frame>Baseline</time_frame>
    <description>Comfort was assessed using a subjective comfort questionnaire. The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. CLUE scores have a range of 0-120.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Reported Vision at Initial Fit Using Contact Lens User Experience (CLUE)</measure>
    <time_frame>Baseline</time_frame>
    <description>Vision at initial fit was assessed using a subjective vision questionnaire. The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0 to 120.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Hyperopia</condition>
  <arm_group>
    <arm_group_label>Acuvue Advance Plus/ Acuvue Advance</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Acuvue Advance Plus contact lenses worn first period and Acuvue Advance contact lenses worn second.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acuvue Advance/Acuvue Advance Plus</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Acuvue Advance contact lenses worn first period and Acuvue Advance Plus contact lenses worn second.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Acuvue Advance Plus</intervention_name>
    <description>Silicone hydrogel contact lens.</description>
    <arm_group_label>Acuvue Advance Plus/ Acuvue Advance</arm_group_label>
    <arm_group_label>Acuvue Advance/Acuvue Advance Plus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Acuvue Advance</intervention_name>
    <description>Silicone hydrogel contact lens</description>
    <arm_group_label>Acuvue Advance Plus/ Acuvue Advance</arm_group_label>
    <arm_group_label>Acuvue Advance/Acuvue Advance Plus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject must be at least 18 years of age and no more than 45 years of age.

          -  The subject is a current spherical soft contact lens wearer and willing to wear the
             study lenses on a daily wear basis for the duration of the study (defined as a minimum
             of 6 hours with a minimum of at least 1 month's wear prior to the study).

          -  The subject's optimal verified spherical equivalent distance correction must be
             between +1.00 and + 6.00D.

          -  Any cylinder power must be ≤ 0.75D.

          -  The subject must have visual acuity best correctable to 20/25+3 or better for each
             eye.

          -  The subject must read and sign the Statement of Informed Consent.

          -  The subject must appear able and willing to adhere to the instructions set forth in
             the clinical protocol.

        Exclusion Criteria:

          -  Ocular or systemic allergies or disease which might interfere with contact lens wear.

          -  Systemic disease or use of medication which might interfere with contact lens wear.

          -  Clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal
             staining, or any other abnormalities of the cornea which would contraindicate contact
             lens wear.

          -  Clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection which
             might interfere with contact lens wear.

          -  Any ocular infection.

          -  Any corneal distortion resulting from previous hard or rigid gas permeable contact
             lens wear.

          -  Pregnancy or lactation.

          -  Diabetes.

          -  Infectious diseases (e.g. hepatitis, tuberculosis) or an immuno-suppressive disease
             (e.g. HIV).

          -  Habitual contact lens type is toric, bifocal, in monovision contact lens wear, or is
             worn as extended wear.

          -  Need any near correction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanticoke</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2010</study_first_submitted>
  <study_first_submitted_qc>October 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2010</study_first_posted>
  <results_first_submitted>September 17, 2013</results_first_submitted>
  <results_first_submitted_qc>December 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2014</results_first_posted>
  <last_update_submitted>May 6, 2015</last_update_submitted>
  <last_update_submitted_qc>May 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperopia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This is a 3 site, 3 visit, randomized, double-masked, bilateral crossover trial comparing Acuvue Advance to Acuvue Advance Plus lenses.</recruitment_details>
      <pre_assignment_details>Of the 38 subjects enrolled, 2 were ineligible and not-randomized, 3 discontinued, and 33 completed as cohort.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Acuvue Advance Plus/ Acuvue Advance</title>
          <description>Group 1 wore AAP first and AA second. Group 2 wore AA first and AAP second</description>
        </group>
        <group group_id="P2">
          <title>Acuvue Advance/ Acuvue Advance Plus</title>
          <description>Group 1 wore AAP first and AA second. Group 2 wore AA first and AAP second</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>1-Week Follow-Up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Final Visit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline summary was conducted on subjects who successfully completed the study. There were 38 subjects that started, 3 discontinued, and 2 were ineligible.</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>Subjects who were randomized and successfully completed the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.8" spread="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity One Week After Lens Wear</title>
        <description>Visual acuity was measured using ETDRS visual acuity test. ETDRS stands for Early Treatment Diabetic Retinopathy Study. Binocular and monocular measurements were collected.</description>
        <time_frame>1 week</time_frame>
        <population>Subjects analyzed were those who were enrolled, randomized, and completed the study. Both monocular and binocular measurements were taken and included in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Acuvue Advance Plus</title>
            <description>Acuvue Advance Plus contact lenses-Binocular measurements</description>
          </group>
          <group group_id="O2">
            <title>Acuvue Advance</title>
            <description>Acuvue Advance contact lenses - Binocular Measurements</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity One Week After Lens Wear</title>
          <description>Visual acuity was measured using ETDRS visual acuity test. ETDRS stands for Early Treatment Diabetic Retinopathy Study. Binocular and monocular measurements were collected.</description>
          <population>Subjects analyzed were those who were enrolled, randomized, and completed the study. Both monocular and binocular measurements were taken and included in analysis.</population>
          <units>LogMAR</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low Luminance/ High Contrast (Binocular)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.082"/>
                    <measurement group_id="O2" value="0.10" spread="0.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Luminance/ High Contrast (Monocular)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.100"/>
                    <measurement group_id="O2" value="0.14" spread="0.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Luminance/ Low Contrast (Binocular)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.075"/>
                    <measurement group_id="O2" value="0.13" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Luminance/ Low Contrast (Monocular)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.108"/>
                    <measurement group_id="O2" value="0.21" spread="0.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Low Luminance/ High Contrast grouping (Monocular):
Ho: The test lens (Acuvue Advance Plus) will be non-inferior to the control lens (Acuvue Advance).
Ha: The test lens (Acuvue Advance Plus) will be &lt;= to the control lens (Acuvue Advance).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is assessed with a margin of -0.05logMAR.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.007</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0059</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0044</ci_lower_limit>
            <ci_upper_limit>0.0187</ci_upper_limit>
            <estimate_desc>The mean difference is defined by: Test lens (Acuvue Advance Plus) - control lens (Acuvue Advance)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>High Luminance/ Low Contrast grouping (Binocular):
Ho: The test lens (Acuvue Advance Plus) will be non-inferior to the control lens (Acuvue Advance).
Ha: The test lens (Acuvue Advance Plus) will be &lt;= to the control lens (Acuvue Advance).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is assessed with a margin of -0.05 logMAR.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.003</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0059</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0086</ci_lower_limit>
            <ci_upper_limit>0.0146</ci_upper_limit>
            <estimate_desc>The mean difference is defined by: Test lens (Acuvue Advance Plus) - control lens (Acuvue Advance)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity at Time of Initial Fit</title>
        <description>Visual acuity will be measured using ETDRS visual acuity test. ETDRS stands for Early Treatment Diabetic Retinopathy Study.</description>
        <time_frame>After 10-15 minutes of lens wear</time_frame>
        <population>Analysis is conducted on those were enrolled and completed the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Acuvue Advance Plus</title>
            <description>Acuvue Advance Plus contact lenses worn</description>
          </group>
          <group group_id="O2">
            <title>Acuvue Advance</title>
            <description>Acuvue Advance contact lenses worn</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity at Time of Initial Fit</title>
          <description>Visual acuity will be measured using ETDRS visual acuity test. ETDRS stands for Early Treatment Diabetic Retinopathy Study.</description>
          <population>Analysis is conducted on those were enrolled and completed the trial.</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low Luminance/High Contrast (Binocular)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.087"/>
                    <measurement group_id="O2" value="0.11" spread="0.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Luminance/High Contrast (Monocular)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.106"/>
                    <measurement group_id="O2" value="0.15" spread="0.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Luminance/Low Contrast (Binocular)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.076"/>
                    <measurement group_id="O2" value="0.13" spread="0.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Luminance/Low Contrast (Monocular)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.123"/>
                    <measurement group_id="O2" value="0.21" spread="0.111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Low Luminance/ High Contrast Grouping (Monocular):
Ho: The test lens (Advance Plus) will be non-inferior to the control lens (Advance).
Ha: The test lens (Advance Plus) will be &lt;= to the control lens (Advance).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is assessed with a margin of -0.05 logMAR.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.016</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0061</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0041</ci_lower_limit>
            <ci_upper_limit>0.0282</ci_upper_limit>
            <estimate_desc>Mean difference represents: Test lens (Advance Plus) - Control lens (Advance).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For High Luminance/ Low Contrast Grouping (Binocular):
Ho: The test lens (Advance Plus) will be non-inferior from the control lens (Advance).
Ha: The test lens (Advance Plus) will be &lt;= to the control lens (Advance).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is assessed with a margin of -0.05 logMAR.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.021</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.006</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0090</ci_lower_limit>
            <ci_upper_limit>0.3305</ci_upper_limit>
            <estimate_desc>Mean Difference is defined to be: test lens (Advance Plus) - control lens (Advance).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Contact Lens Comfort Using Contact Lens User Experience (CLUE)</title>
        <description>The subjective comfort questionnaire CLUE, assesses the overall lens comfort. The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0 to 120.</description>
        <time_frame>1 week</time_frame>
        <population>Analysis was on those who were enrolled and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Acuvue Advance Plus</title>
            <description>Acuvue Advance Plus contact lenses worn.</description>
          </group>
          <group group_id="O2">
            <title>Acuvue Advance</title>
            <description>Acuvue Advance contact lenses worn.</description>
          </group>
        </group_list>
        <measure>
          <title>Contact Lens Comfort Using Contact Lens User Experience (CLUE)</title>
          <description>The subjective comfort questionnaire CLUE, assesses the overall lens comfort. The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0 to 120.</description>
          <population>Analysis was on those who were enrolled and completed the study.</population>
          <units>CLUE points</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" spread="3.28"/>
                    <measurement group_id="O2" value="50.7" spread="3.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Reported Vision Using Contact Lens User Experience (CLUE).</title>
        <description>Overall vision was assessed by a subjective vision questionnaire. The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0 to 120.</description>
        <time_frame>1 week</time_frame>
        <population>Analysis was on those who were enrolled and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Acuvue Advance Plus</title>
            <description>Acuvue Advance Plus contact lenses worn.</description>
          </group>
          <group group_id="O2">
            <title>Acuvue Advance</title>
            <description>Acuvue Advance contact lenses worn.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Reported Vision Using Contact Lens User Experience (CLUE).</title>
          <description>Overall vision was assessed by a subjective vision questionnaire. The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0 to 120.</description>
          <population>Analysis was on those who were enrolled and completed the study.</population>
          <units>CLUE points</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5" spread="2.87"/>
                    <measurement group_id="O2" value="39.9" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Contact Lens Comfort at Initial Fit Using Contact Lens User Experience (CLUE)</title>
        <description>Comfort was assessed using a subjective comfort questionnaire. The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. CLUE scores have a range of 0-120.</description>
        <time_frame>Baseline</time_frame>
        <population>Analysis was on those who were enrolled and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Acuvue Advance Plus</title>
            <description>Acuvue Advance Plus contact lenses worn</description>
          </group>
          <group group_id="O2">
            <title>Acuvue Advance</title>
            <description>Acuvue Advance contact lenses worn</description>
          </group>
        </group_list>
        <measure>
          <title>Contact Lens Comfort at Initial Fit Using Contact Lens User Experience (CLUE)</title>
          <description>Comfort was assessed using a subjective comfort questionnaire. The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. CLUE scores have a range of 0-120.</description>
          <population>Analysis was on those who were enrolled and completed the study.</population>
          <units>CLUE points</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3" spread="3.14"/>
                    <measurement group_id="O2" value="59.0" spread="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Reported Vision at Initial Fit Using Contact Lens User Experience (CLUE)</title>
        <description>Vision at initial fit was assessed using a subjective vision questionnaire. The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0 to 120.</description>
        <time_frame>Baseline</time_frame>
        <population>Subjects analyzed included only those who were enrolled and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Acuvue Advance Plus</title>
            <description>Acuvue Advance Plus contact lenses worn</description>
          </group>
          <group group_id="O2">
            <title>Acuvue Advance</title>
            <description>Acuvue Advance contact lenses worn</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Reported Vision at Initial Fit Using Contact Lens User Experience (CLUE)</title>
          <description>Vision at initial fit was assessed using a subjective vision questionnaire. The CLUE Questionnaire is a validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0 to 120.</description>
          <population>Subjects analyzed included only those who were enrolled and completed the study.</population>
          <units>CLUE points</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" spread="3.90"/>
                    <measurement group_id="O2" value="49.6" spread="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month, Study took place from Oct 1, 2010-Nov 12, 2010</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Acuvue Advance Plus</title>
          <description>Acuvue Advance Plus contact lenses</description>
        </group>
        <group group_id="E2">
          <title>Acuvue Advance</title>
          <description>Acuvue Advance contact lenses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brian Pall, O.D., M.S., F.A.A.O. Principal Research Optometrist</name_or_title>
      <organization>Johnson &amp; Johnson Vision Care</organization>
      <phone>1 904 443-1290</phone>
      <email>bpall@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

